The mark of a company that put an antidote in the box - before anyone asked for one.
Clinical-Stage Biopharma
Basking Biosciences
MORRISVILLE, NORTH CAROLINA | FOUNDED 2019 | STROKE & THROMBOSIS
MORRISVILLE, NORTH CAROLINA | FOUNDED 2019 | STROKE & THROMBOSIS
The Scene
It is the worst ninety minutes of someone's life, and a clock is the enemy. A clot has shut off blood to part of the brain. Every minute, roughly two million neurons go dark. The doctor reaches for the one approved clot-buster and hesitates - because the same drug that might save this patient could also start a bleed it cannot stop.
Basking Biosciences exists for that hesitation. The company is building the first reversible thrombolytic for acute ischemic stroke: a drug designed to dissolve the clot quickly, then get out of the way fast, with a companion agent that can switch it off in minutes if things go wrong. In a field where the standard of care has barely changed in decades, that is a genuinely different proposition - which is, of course, exactly why no one had done it yet.
The Problem They Saw
For most stroke patients, the pharmacological menu is short. Tissue plasminogen activator - tPA - works by cranking up the body's own clot-dissolving machinery. It can be remarkable. It can also cause bleeding, including in the brain, and once it is in, there is no taking it back. The therapeutic window is narrow, the eligibility rules are strict, and a meaningful share of patients arrive at the hospital already outside of it.
The founders looked at that picture and asked an awkward question: what if the problem was not the idea of dissolving a clot, but the lack of control? A drug you cannot dial back forces doctors to be conservative. Conservative means patients get left out. Being left out, in stroke, has a cost measured in lost function and lost time.
So the target was not just a better clot-buster. It was control: rapid onset, short action, and - the part everyone else skipped - a reversal agent built alongside the therapy, not bolted on years later.
The Founders' Bet
The science did not begin in a pitch deck. It began roughly sixteen years ago in a laboratory at Duke University, where a med/Ph.D. student named Shahid Nimjee worked with his professor, Bruce Sullenger, on RNA aptamers - short, folded strands of RNA that can bind a target protein with the specificity of an antibody and, crucially, can be paired with a complementary strand that switches them off.
That last property is the whole bet. An aptamer with a matching antidote is a drug with a dimmer switch. In 2019, Sullenger and Nimjee turned the research into a company, with Duke's Fuqua alumnus Richard Shea helping build the business around it. They pointed the platform at the place where reversibility matters most: the bleeding-versus-clotting tightrope of acute stroke.
Neurosurgeon-scientist who carried the aptamer work from a Duke bench to the clinic; the stroke clinical lead.
Pioneer of RNA aptamer therapeutics whose lab seeded the company's core technology and its controllable design.
Biopharma company-builder (ex-Millendo, ex-Ananke) who took the CEO seat in October 2025 to steer clinical execution.
Duke Fuqua alumnus who helped found and structure the company around the founders' science.
The Product
Most therapies target fibrin, the mesh that holds a clot together. BB-031 takes a different road. It is a first-in-class RNA aptamer designed to inhibit von Willebrand Factor (vWF) - a protein that helps platelets stick and clots form. Hit vWF with precision and you can break up the clot while, in theory, leaving the rest of the clotting system less disturbed. It is meant to act quickly and clear quickly.
A first-in-class RNA aptamer that inhibits von Willebrand Factor with high specificity. Rapid onset, short acting. Now in the Phase 2 RAISE trial for acute ischemic stroke.
A direct-acting reversal agent designed to bind and neutralize BB-031 within minutes - so thrombolytic activity can be shut down if bleeding appears. In Phase 1 testing.
Milestones
RNA aptamer research begins at Duke University in Bruce Sullenger's lab, with Shahid Nimjee as a student.
Sullenger and Nimjee spin the science into Basking Biosciences, based in North Carolina's Research Triangle.
Round led by ARCH Venture Partners closes, funding clinical development of BB-031 and BB-025.
The Phase 2 RAISE proof-of-concept trial of BB-031 for acute ischemic stroke gets underway.
First patients dosed in Part B of the Phase 2 trial; a $27.5M tranche unlocks; Julia C. Owens, Ph.D. named CEO.
First participants dosed in the Phase 1 study of reversal agent BB-025.
The Proof
Conviction is cheap; syndicates are not. Basking's $55M financing was led by ARCH Venture Partners, with Insight Partners, Platanus, Solas BioVentures and RTW Investments joining new, alongside existing backers Longview Ventures, Rev1 Ventures and The Ohio State University. Total funding to date sits north of $60M. That is the kind of room a small team needs to run two clinical programs at once.
The Mission
Basking's stated mission is to redefine thrombosis treatment with a targeted, short-acting therapy and a direct-acting reversal agent. Strip away the jargon and it reads like a transfer of power: from the drug's pharmacology back to the physician's judgment. If a treatment can be reversed, the calculus at the bedside changes. More patients become candidates. Fewer doctors have to choose between doing nothing and doing something they cannot undo.
The company keeps a foothold on two continents - North Carolina's Research Triangle and Queensland, Australia - and runs lean, fewer than two dozen people steering two clinical programs. Small, in this business, is not a weakness. It is focus with a deadline.
Why It Matters Tomorrow
Return to that hospital room. The clock is still the enemy. The clot has still shut off the blood. But imagine the doctor's hesitation shortened - because the drug in the syringe is fast, short-lived, and carries its own antidote. If a bleed starts, there is something to give. The decision gets easier. The window gets wider. The patient who would have been turned away gets a chance.
None of this is settled. BB-031 is mid-trial; BB-025 is early; biology humbles people for a living, and most drugs that look elegant in a slide deck never reach a pharmacy. Skeptics are right to wait for the data. But the bet itself is clean and worth understanding: control beats power when a life is on the timer. Basking Biosciences is spending its years, and its investors' money, to find out whether a clot-buster with an off switch can change what happens in those ninety minutes.
If it works, the most important feature of their drug will be the one you hope is never used.